Vicore: Encouraging IPF Interim Data, Follow up - Redeye - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

Vicore: Encouraging IPF Interim Data, Follow up - Redeye

{newsItem.title}

Redeye gives an additional comment on yesterday’s interim data in Vicore’s phase II IPF study. While early and indicative, we find the results very encouraging and potentially game-changing if replicated in the final study (and subsequent phase IIb and III studies). We slightly increase our already aggressive LoA and raise our base case to SEK 64 (62).

Länk till analysen i sin helhet: https://www.redeye.se/research/832629/vicore-encouraging-ipf-interim-data-follow-up?utm_source=finwire&utm_medium=RSS

Nyheter om Vicore Pharma

Läses av andra just nu

Om aktien Vicore Pharma

Senaste nytt